In the light of novel cancer immune therapies, the status of antitumor inflammatory response and its regulation has gained much attention in patients with lung cancer. Ample datasets exist for non-small-cell lung cancer, but those for pulmonary neuroendocrine tumors are scarce and controversial. Here, tumor-associated inflammation, CD8+ cell infiltration and PD-L1 status were evaluated in a cohort of 57 resected carcinoids and 185 resected neuroendocrine carcinomas of the lung (58 large cell carcinomas and 127 small cell carcinomas). Data were correlated with clinicopathological factors and survival. Moderate or high tumor-associated inflammation was detected in 4 carcinoids (7%) and in 37 neuroendocrine carcinomas (20%). PD-L1 immunoreactivity was seen in immune cells of 73 (39%) neuroendocrine carcinomas, while tumor cells were labeled in 21 (11%) cases. Inflammatory cells and tumor cells in carcinoids lacked any PD-L1 expression. In neuroendocrine carcinomas, PD-L1 positivity in immune cells, but not in tumor cells, was associated with intratumoral CD8+ cell infiltration (P < 0.001), as well as with the severity of tumor-associated inflammation (P < 0.001). In neuroendocrine carcinomas, tumor-associated inflammation and PD-L1 positivity in immune cells correlated with prolonged survival and the latter factor was also an independent prognosticator (P < 0.01, hazard ratio 0.4 for overall survival, P < 0.001 hazard ratio 0.4 for disease-free survival). Taken together, in neuroendocrine tumors, antitumor inflammatory response and PD-L1 expression are largely restricted to neuroendocrine carcinomas, and in this tumor entity, PD-L1 expression in inflammatory cells is positively correlated to patient survival.
are subclassified into typical and atypical carcinoids on the basis of mitotic count and/or presence of necrosis. Although atypical carcinoids are more likely to metastasize and have a worse prognosis, these two neoplasms share the same phenotype and genotype (Simbolo et al. 2017) . In contrast to carcinoids, SCLC and LCNEC are highgrade neuroendocrine carcinomas (NEC) (Travis et al. 2015) . Patients with these malignancies share similar clinical features, e.g. higher incidence in males than in females, strong association with cigarette smoking, early metastasis and dismal prognosis (Asamura et al. 2006) . Also, the genetic profiles of the two NEC types are largely overlapping (Rekhtman et al. 2016 , Simbolo et al. 2017 . Moreover, the few patients who are amenable to surgical treatment benefit from adjuvant chemotherapy .
Programmed death-ligand 1 (PD-L1) is a transmembrane protein that regulates immune cell activity through binding to its receptor, programmed death protein 1 (PD-1), expressed on inflammatory cells. The interaction of PD-L1 and PD-1 inhibits antitumor immune response through negative regulation of T-cell proliferation and cytokine production. Therefore, blockade of the PD-L/PD-1 pathway has become one of the most promising therapeutic options in various human malignancies including lung cancer (Brahmer et al. 2015 , Herbst et al. 2016 , Massard et al. 2016 , Reck et al. 2016 , Rittmeyer et al. 2017 .
Pembrolizumab, a monoclonal antibody against PD-1, was reported to prolong survival in patients with metastasized non-small-cell lung cancer (NSCLC) (Reck et al. 2016) . This study, as well as multiple additional clinical trials with a variety of other immune checkpoint inhibitors (Brahmer et al. 2015 , Rittmeyer et al. 2017 , has defined PD-L1 protein expression detected by immunohistochemistry as a valid biomarker for selecting patients who will benefit from immune checkpoint inhibitory agents. Although patient selection by PD-L1 expression is, due to various reasons, by no means perfect, this biomarker is the only currently approved method to predict response in NSCLC (Gridelli et al. 2017) . Currently, PD-L1 staining is established as a companion diagnostic biomarker in first-line (>50% positivity in tumor cells) treatment of metastasized NSCLC patients prior to therapy with pembrolizumab and in second-line (>1% positivity in tumor cells) treatment of metastasized NSCLC, again prior to therapy with pembrolizumab.
Despite recent progress in the understanding of immune regulation in NSCLC, the role of antitumor immunity in neuroendocrine tumors of the lung is far less clear. A clinical study has recently reported the efficacy and safety of pembrolizumab in patients with advanced SCLC (Ott et al. 2017) . However, data regarding PD-L1 expression in pulmonary neuroendocrine tumors are sparse, only fragmented data are available especially in carcinoids and LCNEC (Fan et al. 2016 , Tsuruoka et al. 2017 . Recently, some studies reported on PD-L1 immunoreactivity in mostly small cohorts of SCLC (Ishii et al. 2015 , Schultheis et al. 2015 , Berghoff et al. 2016 , Fan et al. 2016 , Miao et al. 2016 , Tsuruoka et al. 2017 , Yu et al. 2017 ). However, the reported incidence and localization of PD-L1 expression varied considerably, probably due to the fact that differing antibodies were used and/or variable cutoff values were applied. In addition, often expression was investigated in tissue microarrays (Schultheis et al. 2015 , Berghoff et al. 2016 , Fan et al. 2016 , Miao et al. 2016 , Tsuruoka et al. 2017 . In this context, it is important to note that antibody/cutoff selection is crucial in the evaluation of PD-L1 positivity in NSCLC (Scheel et al. 2016 (Scheel et al. , 2017 .
The aim of this study is to clarify the status and clinical impact of inflammatory response and PD-L1 expression in a large series of surgically resected neuroendocrine tumors of the lung, employing a rigorously standardized methodology.
Materials and methods

Tissues and patients' characteristics
Consecutive tissue samples from 242 patients with pulmonary neuroendocrine tumors (57 patients with carcinoids, and 185 patients with NEC), who underwent surgical resection at 10 institutions in Japan between 1996 and 2015 were included into the study (Supplementary  Table 1 , see section on supplementary data given at the end of this article). All tumors were primaries, recurrences were excluded. Detailed clinical information was obtained for 225 patients (93%; 168 patients with NEC and 57 patients with carcinoids) (Table 1) . Clinical follow-up data was available for 224 patients (167 patients with NEC and 57 patients with carcinoids). Among 212 patients, for whom post-operative treatment information was available, 95 patients (45%) received adjuvant therapy (CDBCA/VP16 37%, CDDP/VP16 24%, CDDP/CPT11 13%, CDBCA/CPT11 6%, CDBCA/ETP 3%, others 19%). Histological diagnoses were confirmed after extensive reviewing of the specimens by five pathologists including two neuroendocrine tumor experts (AK and HS) and three lung pathology experts (TK, YI and WW) , who based their assessment on the criteria of the 2015 WHO classification (Travis et al. 2015) . The mean follow-up time was 42 months (72 and 32 months for carcinoids and NECs, respectively). Three patients (two with LCNEC and 1 with SCLC) died within 1 month of surgery and were excluded from the survival analyses. All tumors were reclassified according to the 8th edition of the TNM classification (Brierley et al. 2017) . The study has been approved by the ethics committees of all participating institutions.
Immunohistochemistry and evaluation
Serial 3-μm tissue sections from paraffin blocks were prepared.
For immunohistochemistry, a mouse monoclonal antibody directed against PD-L1 (clone 22C3, dilution 1:30, Dako, Glostrup, Denmark -the companion diagnostic antibody used in all Pembrolizumab studiesand a mouse monoclonal antibody directed against CD8 (clone C8/144B, dilution 1:100, Dako) as well as a mouse monoclonal antibody directed against CD68 (clone KP1, dilution 1:10,000, Dako) were used. Immunohistochemical stainings were performed using an automated staining module (BenchMark XT system, Roche/Ventana Medical Systems, Tuscon, AZ, USA). Briefly, for PD-L1 staining tissue sections were deparaffinized with EZ Prep (Roche/Ventana Medical Systems) at 75°C, heat pretreated in Cell Conditioning 1 (CC1) for antigen retrieval at 76°C-100°C and then incubated with the primary antibody for 32 min at 37°C after inactivation of the endogenous peroxidase using UV inhibitor for 4 min at 37°C. Slides were then incubated with a HRP Universal Multimer (Roche/Ventana Medical Systems) for 8 min. Antibody binding was detected using DAB as chromogen and slides were counterstained with hematoxylin. To ascertain staining quality, rigorous standards were applied, including internal and external positive/negative controls (Fig. 1H ). The quality of staining was ascertained by participation in various round robin trials (Scheel et al. 2016 (Scheel et al. , 2017 .
Tumor-associated inflammation was assessed by two observers (AK and NO) as previously described (Kasajima et al. 2010) . Briefly, a full-section hematoxylin-eosin (H&E) slide was screened for tumor-associated inflammation (including lymphocytes, macrophages and granulocytes), which was graded as absent (no inflammatory cells at the tumor margin), weak (mild and patchy inflammatory cells at the tumor margin), moderate (prominent bandlike inflammatory reaction at the tumor margin) or Table 1 Clinicopathological characteristics of 225 patients with neuroendocrine tumors of the lung. (100) 39 (17) 18 (8) 53 (24) 115 ( 2.6 ± 1.5 2.1 ± 1.4 3.1 ± 2.4 3.1 ± 1.5 2.6 ± 1.3 pT a pT1a,b,c 122 (55) 29 (74) 9 (56) 18 (35) 66 (58) pT2a,b
71 (32) 9 (23) 4 (25) 25 (48) 33 (29) pT3 22 (10) 0 (0) 1 (6) 7 (13) 14 (12) pT4 5 (2) 
149 (72) 36 (97) 12 (75) 30 (61) 71 (67) pN1, 2, 3
59 (28) 1 (3) 4 (25) 19 (39) 35 (33) pM a pM0 210 (95) 39 (100) 16 (100) 49 (94) 106 (94) (59) 35 (90) 10 (63) 24 (46) 62 (54) pStage II-IV 90 (41) 4 (10) 6 (38) 28 (54) 52 (46) Clinical information was not obtainable for 17 patients of our cohort. Data not available in a 5, b 17, and c 4 cases, respectively. LCNEC, large cell neuroendocrine carcinoma; SCLC, small-cell lung carcinoma; s.d., standard deviation. Endocrine-Related Cancer high (florid cup-like inflammation at the invasive edges) without further differentiation of the different cell types (Mohammed et al. 2012) . Cases with absent or weak infiltrates were defined as tumor-associated inflammation negative, while cases with moderate or high infiltrate were defined as positive. CD8+ cells were counted by two observers (AK and AI) in the area of highest immune cell density by using a 40× objective lens. For the assessment of PD-L1, membranous staining in immune cells (IC) and tumor cells (TC) were independently evaluated by three observers (AK, AI and WW). Cases with disagreement were discussed using a multiheaded microscope. The proportion of the tumor area occupied by PD-L1-positive cells was scored regardless of PD-L1 staining intensity. A score of <1% was considered as PD-L1 negative, a score of ≥1% was considered as PD-L1 positive (Herbst et al. 2016 , Ott et al. 2017 .
Statistical analyses
JMP Pro, version 13.1.0 software (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses. The sample distribution between groups was compared using Pearson's chi-square test. The Wilcoxon test was applied for the comparison of continuous values or scores between groups. The probability of differences in overall survival (OS) and disease-free survival (DFS) was determined using the Kaplan-Meier method, with a log-rank test to probe for significance. Multivariate analysis was undertaken with the Cox model of proportional hazards. A P value of <0.05 was considered statistically significant.
Results
Patients' characteristics and clinical relevance of standard pathological factors
Thirty-nine patients (17%) had a typical carcinoid, 18 patients (7%) an atypical carcinoid, 58 patients (24%) a LCNEC and 127 patients (52%) a SCLC ( Table 1 ). The associations of clinicopathological parameters with survival of patients with carcinoids and NECs are shown in Supplementary Tables 2 and 3 , respectively. Univariate survival analysis of patients with NEC revealed ≥pN1 and ≥pStage II as adverse prognosticators for OS (P < 0.0001 for pN, P = 0.004 for pStage) as well as for DFS (P < 0.0001 for pN, P = 0.002 for pStage). Significant prognostic factors obtained from univariate analyses were included into multivariate analyses (see the 'Correlation of tumorassociated inflammation and PD-L1 immunoreactivity with survival' section below).
Tumor-associated inflammation and CD8+ cell infiltrate
Moderate/high inflammation was observed in only 4 (7%) carcinoid tumors (one typical and 3 atypical), but in 37 NECs (20%, P < 0.0001; 12 LCNEC, 25 SCLC) ( Fig. 1 and Table 2 ). The degree of CD8+ cell infiltration ( Fig. 1 ) was positively correlated with tumor-associated inflammation (mean number 76 in the negative group, 156 in the positive group, P < 0.0001, Fig. 2 ). The number of CD8+ cells was significantly higher in NEC (mean 92) than in carcinoids (mean 12, P < 0.0001). The number of CD8+ cells was higher in atypical carcinoids (mean 19) than in typical carcinoids (mean 7, P = 0.05), no difference was found between LCNEC and SCLC (mean 83 vs mean 97) ( Table 2) .
Immunohistochemical PD-L1 expression
In carcinoid tumors, PD-L1 immunoreactivity was not detected in either IC or TC (IC: 0%, TC: 0%). In NEC, PD-L1 immunoreactivity ≥1% was seen in IC in Table 3 ). Most of the PD-L1-positive ICs were directly associated with tumor cell nests (Fig. 1) . The overall location and distribution of PD-L1-positive cells was equivalent to those of CD68-expressing macrophages on consecutive sections (Fig. 1) . In contrast, CD8+ cells were only sparsely distributed in the corresponding areas of the tumors (Fig. 1) . IC cell characteristics were determinable by morphology in 62 IC PD-L1-positive NEC; 39 NEC (76%) expressed PD-L1 only in macrophages, 23 NEC (24%) expressed PD-L1 both in macrophages and lymphocytes. No significant difference was detected for PD-L1 expression in IC between LCNEC and SCLC (Table 2) . PD-L1 positivity in IC was significantly correlated with the number of CD8+ cells (Fig. 2) . PD-L1 immunoreactivity in TC was scarcely detected. Only 21 NECs (12%) were found to be positive (≥1%) and even these cases usually showed a low percentage of positive cells. None of the tumors expressed PD-L1 in ≥50% of TC, PD-L1 positivity in TC ranged from 0 to 30%. No differences were detected in tumor-associated inflammation and PD-L1 status in TC between LCNEC and SCLC ( Table 2 ). The number of CD8+ cells did not differ between tumors with and without PD-L1 immunoreactivity in TC (Fig. 2) .
Correlation of tumor-associated inflammation and PD-L1 immunoreactivity with survival
In patients with carcinoids, no prognostic impact was detected for tumor-associated inflammation. Survival impact of PD-L1 expression in carcinoids could not be assessed due to the complete absence of PD-L1 expression in both TC and IC in our cohort. NEC patients with moderate/high tumor-associated inflammation showed a significantly prolonged OS (P = 0.03) and DFS (P = 0.03, Fig. 3 and Table 3 ). The same was true for NEC with high PD-L1 expression in IC (P = 0.03 for OS and P = 0.003 for DFS, Fig. 3 and Table 3 ). Since PD-L1 positivity in IC was usually seen in macrophages, we assessed whether the positive survival impact of PD-L1-expressing IC was a mere consequence of stronger macrophage infiltration in these tumors. However, macrophage infiltration in NEC by itself had no survival impact and when stratified for both parameters combined (PD-L1 positivity/macrophage infiltration) only those patients with PD-L1-positive macrophages had a survival advantage compared to patients without macrophages (with or without other PD-L1-positive inflammatory cells) and patients with macrophages, which do not express PD-L1 ( Supplementary  Fig. 1 ). PD-L1 expression in TC of NEC had no prognostic implication.
A multivariate survival analysis including tumor size, local tumor extent (pT), absence or presence of lymph node metastases (pN), tumor-associated inflammation and PD-L1 immunoreactivity in IC showed an independent poor prognostic impact for the presence of lymph node metastasis (≥pN1, HR 2.6 (95% CI 1.6-4.4) P = 0.001 for OS, ≥pN1, HR 2.5 (95% CI 1.6-3.9) P < 0.0001 for DFS) and an independent favorable prognostic impact for PD-L1 immunoreactivity in IC (HR 0.4 (95% CI 0.2-0.7) P = 0.001 for OS, HR 0.4 (95% CI 0.3-0.7) P = 0.001) ( Table 4) .
Discussion
In this study investigating the so far largest pulmonary neuroendocrine tumor cohort, we demonstrate an association between severity of antitumor inflammation as well as of PD-L1 expression in IC and favorable prognosis in pulmonary NEC. Our results indicate that T-cell-mediated antitumor immunity seem to play a role in high-grade neuroendocrine tumors of the lung, but not in carcinoids, suggesting that the latter group of pulmonary neoplasms is 'immune deserted'.
The status of PD-L1 expression in lung neuroendocrine tumor has previously not been fully established; most series were small in number, employed tissue microarrays and/or included a limited number of histological types (Supplementary Table 4 ) (Ishii et al. 2015 , Schultheis et al. 2015 , Berghoff et al. 2016 , Fan et al. 2016 , Miao et al. 2016 , Tsuruoka et al. 2017 , Yu et al. 2017 . In our study, a large number of surgically resected SCLC could be included, mainly due to the frequent usage of lung cancer surveillance in Japan, which results in the detection of a higher rate of potentially resectable SCLC at the time of diagnosis. This uniqueness in our cohort allowed for a more precise evaluation of the inflammatory status in NEC, compared to what can be achieved in cohorts of biopsy specimen or tissue microarrays.
Interestingly, we found PD-L1 expression in intratumoral IC to be prognostic in NEC. An association of PD-L1 expression in IC, but not in TC with a favorable prognosis in SCLC patients has also been reported in one of the previous studies that addressed this issue (Berghoff et al. 2016) and in extrapulmonary human malignancies (Bellmunt et al. 2015 , Darb-Esfahani et al. 2016 . PD-L1 expression in IC has also been reported to be correlated with high-histologic grade and solid subtype in NSCLC (Driver et al. 2017) . The detailed mechanisms of PD-L1 overexpression in IC and the reason for its association with a better prognosis are largely unknown. A compensatory upregulation of PD-L1 expression by proinflammatory cytokines that are generated in the tumor microenvironment has been discussed as one potential option (Darb-Esfahani et al. 2016) .
Our observation that most PD-L1-expressing ICs in NEC were macrophages indicated that this cell type might be centrally involved into the antitumor inflammatory reaction in this tumor entity. It has been reported that inflammation-associated signals by TNF-alpha induce inflammatory monocytes/macrophages expressing PD-L1 in the tumor microenvironment (Hartley et al. 2017) . Moreover, an inhibitory function of PD-L1 expressing intratumoral macrophages on T-cell proliferation has been observed in tumor tissues (Wang et al. 2017) . Thus, our results, in the light of these former findings, further support the hypothesis that PD-L1 expressed in intratumoral macrophages might be a tumor-induced protective mechanism against antitumor inflammation in pulmonary NEC. This tumor protective function was likely dependent on the ability of macrophages to express PD-L1, since the density of macrophages in itself had no prognostic impact whatsoever in our cohort. Multiple clinical trials are currently evaluating the efficacy and safety of immune checkpoint inhibitors in SCLC (Karachaliou et al. 2017) . Some preliminarily results demonstrated a favorable response rate and manageable toxicity (Antonia et al. 2016) . Recently, the first large dataset on immune checkpoint therapy in pulmonary neuroendocrine tumors was fully published; in this study, pembrolizumab proved to be effective in a subset of patients with these tumors (Ott et al. 2017) . From these studies, somewhat controversial results emerged with respect to the predictive value of PD-L1 immunoreactivity in tumor cells, with the majority of investigations showing only minor effects. Regrettably, none of the studies reported on the predictive effect of immune cell positivity for PD-L1 in these scenarios.
Multiple PD-L1 antibodies are commercially available, of which especially four (22C3, 28-8, SP142, SP263) have been used as clinical trial assays in the context of currently available immune checkpoint inhibitor treatment (Scheel et al. 2016 (Scheel et al. , 2017 . Some previous studies have investigated PD-L1 expression in neuroendocrine tumors of the lung applying a wide range of different antibodies and staining/ evaluation methods (Supplementary Table 4) , which may account for the heterogeneous results reported. Ours is the first study in pulmonary neuroendocrine tumors that analyzed PD-L1 expression employing the 22C3 clone in the context of a rigorous quality controlled assay setup. Since we have recently shown that PD-L1 staining results for three of the trial antibodies (SP263, 22C3, 28-8) are well comparable, when used in a quality controlled way (Scheel et al. 2016 (Scheel et al. , 2017 . We believe that our data obtained with the 22C3 antibody can be seen as representative and are transferable to other trial antibody scenarios.
The following limitations apply to our study. First, we cannot exclude a certain selection bias due to the inclusion of only surgically resected patients in earlier stages in our cohort. Second, since this is a multi-institutional cohort, potential inter-institutional variability in adjuvant treatment and post-operative surveillance methods might have a confounding influence in our dataset. A platinum-based chemotherapy was performed in all NEC patients, but the chemotherapeutic partner used was variable, as was the number and timing of chemotherapy cycles applied. A phase III clinical study conducted by the Japan Clinical Oncology Group (JCOG1205/1206, HGNEC-EP/IP-P3) to determine the optimal adjuvant chemotherapy in resected NEC patients is currently ongoing. To date, however, a standardized adjuvant therapy or post-operative monitoring protocol for patients with SCLC/LCNECs is lacking. Third, some clinical data were missing in our cohort such as e.g. WHO performance status. And although our mean follow-up for carcinoid tumor patients was more than 5 years, even longer follow-up times could be potentially useful for this group of quite indolent tumors (Cao et al. 2011) . All mentioned limitations are very hard to avoid when studying tissue cohorts of pulmonary neuroendocrine tumors, which are rare and in case of SCLC are only very occasionally resected in most countries. To assemble an extremely large cohort like ours, one has to go for a logistically demanding assembly of a multi-institutional tumor collection, which -outside a clinical trial -always comes with some data heterogeneity. We nevertheless believe that despite all mentioned limitations, much can be learned from our data set.
In conclusion, we demonstrated antitumor inflammation to be prognostic in NEC of the lung, while it was virtually not present and possibly played no role in carcinoids. The quantity of PD-L1-positive IC, which were mainly macrophages, was closely linked to tumorassociated inflammation and cytotoxic T-cell infiltration and was also indicative of a better prognosis. In the future, it would be interesting to explore the predictive value of inflammation in general and of PD-L1-expressing inflammatory cells in the context of immune checkpoint inhibition.
